PERBANDINGAN EFIKASI DAN KEAMANAN PENGGUNAAN FEBUXOSTAT DAN ALLOPURINOL PADA PASIEN GOUT

Hendra Herman, Sukmawati Sukmawati, Andi Desiah Pranada

Abstract


Febuxostat and allopurinol are xanthine oxidase inhibitors to reduce uric acid levels. The research aimed to determine the differences in efficacy and safety of using febuxostat and allopurinol for gout patients. This research was conducted using a narrative review method for articles obtained from the PubMed and Willey databases published in 2010-2021. From the article exploration, 5 articles were reviewed showing that the determination of drug efficacy was seen by monitoring the changes in uric acid levels for 6 months from the beginning of drug use. Febuxostat and allopurinol had good efficacy in achieving target uric acid levels < 6 mg/dL, however, febuxostat was superior to allopurinol in usual doses. Febuxostat 80 mg had superior efficacy to febuxostat 40 mg, while febuxostat 40 mg had superior efficacy to allopurinol 300 mg (p < 0.05). For safety, febuxostat and allopurinol possessed similar side effects in the form of upper respiratory tract infection, diarrhea, headache, nausea and vomiting.


Keywords


Allopurinol, efficacy, febuxostat, gout, safety.

References


Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam, Edisi 6, Jilid I. Jakarta: Interna Publishing., 2014.

Tanto C, Liwang F, Hanifati S, Pradipta EA. Kapita Selekta Kedokteran, Edisi 4. Jakarta: Media Aescalapius, 2016.

Dipiro JT, Yee GC, Posey M, Haines ST, Nolin TD and Ellingrod VE. Pharmacotherapy: A Pathophysiologic Approach, 11th edn. USA: Mc Graw Hill., 2020.

Riskesdas 2013. Risert Kesehatan Dasar 2013: Kementrian Kesehatan RI. Jakarta: Badan Penelitian dan Pengembangan Kesehatan., 2013.

Perhimpunan Reumaologi Indonesia. Pedoman Diagnosis dan Pengelolaan Gout. Jakarta: Perhimpunan Reumaologi Indonesia, IRA, 2018.

Zahroh C, Faiza K. Pengaruh kompres hangat terhadap penurunan nyeri pada penderita penyakit Artritis Gout, Jurnal Ners Dan Kebidanan (Journal of Ners and Midwifery). 2018;5(3):182-187.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Terkeltaub R. American College of Rheumatology Guidelines for Management of Gout. part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care and Research. 2012;64(10):1431–1446.

Zein CS, Carvalho M, G. Applied Therapeutics: The Clinical Use of Drugs, 11th edn. China: Wolters Kluwer, 2018.

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Research and Therapy. 2010;12(2):16–18.

Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: Efficacy and safety of febuxostat vs allopurinol. BMC Musculoskeletal Disorders. 2012;13.

Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatrics. 2012;12.

Backer MA, MacDonals MA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Africa’s Potential for the Ecological Intensification of Agriculture. 2013;53(9):1689–1699.

Shen X, Li J, Fu Q, Liu L, Gao X, Chen X, Chen P, Wang C. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. Journal of Clinical Pharmacy and Therapeutics. 2019;44(2):318–326.

American College Of Rheumatology. Guidelines For Management of Gout. Atalanta: Lake Boulevard NE, 2020.

Siswanto. Sekilas Tentang Randomized Controlled Trial. Newsletter PTTK&EK. 2012;1(3):01-03.

Pohan S. Jaminan Mutu layanan Kesehatan: Dasar-Dasar Pengertian dan Penerapan. Jakarta: Buku Kedokteran EGC, 2007.

Jordan A, Gresser U Side effects and interactions of the xanthine oxidase inhibitor febuxostat. Pharmaceuticals. 2018.11(2):1-19.

Pandey A, Chaturvedi M, Prakash H, Meena D. Febuxostat - A new treatment for hyperuricaemia in gout. National Journal of Physiology, Pharmacy and Pharmacology. 2012;2(1):23–28.

McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Annals of the Rheumatic Diseases. 1981;40(3):245–249.

Australian Rheumatology Association. Patient information on allopurinol. Australia: Arthritis Australia, 2016.

Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Seminars in Arthritis and Rheumatism. 2015;45(2):174–183.

Paracelcua. The dose alone makes posion. 1993. diakses pada tanggal 25 Mei 2021, http://ace.ace.orst.edu/info/extoxnet/tibs/doseresp.htm.

Riskesdas 2018. Laporan Nasional Riskesdas 2018: Kementrian Kesehatan RI. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, 2018.




DOI: https://doi.org/10.56711/jifa.v13i1.768

Refbacks

  • There are currently no refbacks.


Indexed by:

     

ISSN: 2085-4714 | e-ISSN: 2502-9444

Editor's Address:

Faculty of Pharmacy, Univeristas Muslim Indonesia
2nd Campus of UMI: Jl. Urip Sumoharjo km. 5 , Makassar, South Sulawesi, Indonesia

E-mail: jurnal.farmasi@umi.ac.id

View My Stats